Emma Walmsley

Stories

Roche-backed lung cancer drug clears phase 3 but trails GSK rival on survival

As of September 2026: Leads GSK's ADC push, including Ris-Rez

Two rival antibody-drug conjugates just beat the standard of care in relapsed small-cell lung cancer. Roche-partnered Tam-Peli held median survival at 13.3 months; GSK's competitor got 18.5. Both faced the same decades-old chemotherapy — and that five-month gap is the story.

Updated Sep 14

The race to protect 27 million Americans from accidental food allergen exposure

Money Moves

As of May 2026: Stepped down December 2025; notice period through September 2026

For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.

Updated May 22